Current status of immunotherapy treatments for pancreatic cancer

Journal of Clinical Gastroenterology

Volumn 50, Issue 10, 2016, Pages 836-848

  Jimenez Luna, Cristina ^a   Prados, Jose ^a   Ortiz, Raul ^a,b   Melguizo, Consolacion ^a   Torres, Carolina ^a   Caba, Octavio ^a,b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

Author keywords

clinical trial; immunotherapy; pancreatic cancer

Indexed keywords

CANCER VACCINE; MONOCLONAL ANTIBODY;

ACTIVE IMMUNOTHERAPY; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL OUTCOME; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SUPPRESSOR CELL; SURVIVAL RATE; TREATMENT DURATION; TUMOR ASSOCIATED LEUKOCYTE; IMMUNOTHERAPY; PANCREAS TUMOR;

HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS;

EID: 84981193868     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000623     Document Type: Review

References (170)

1. Farber E. The multistep nature of cancer development. Cancer Res. 1984; 44: 4217-4223
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674
3. Paniccia A, Merkow J, Edil BH, et al. Immunotherapy for pancreatic ductal adenocarcinoma: An overview of clinical trials. Chin J Cancer Res. 2015; 27: 376-391
4. Ehrlich P, Ueber Den Jetzigen. Stand Der Karzinomforschung [The current state of cancer research]. Ned Tijdschr Geneeskd. 1909; 5: 73-290
5. Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J. 1957; 1: 779-786
6. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006; 6: 836-848
7. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3: 991-998
8. Ostrand-Rosenberg S. Immune surveillance: A balance between protumor and antitumor immunity. Curr Opin Genet Dev. 2008; 18: 11-18
9. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21: 137-148
10. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331: 1565-1570
11. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007; 117: 1137-1146
12. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450: 903-907
13. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997; 15: 2403-2413
14. Berlin J.D. Catalano P. Tho et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol. 2002 20 3270-3275
15. Di Marco M, Di Cicilia R, Macchini M, et al. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment?. (Review). Oncol Rep. 2010; 23: 1183-1192
16. Conroy T, Desseigne F, Ychou M, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-1825
17. Amedei A, Niccolai E, Prisco D. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother. 2014; 10: 3354-3368
18. Gajewski TF. Cancer immunotherapy. Mol Oncol. 2012; 6: 242-250
19. Wormann SM, Diakopoulos KN, Lesina M, et al. The immune network in pancreatic cancer development and progression. Oncogene. 2014; 33: 2956-2967
20. Lucas S, Coulie PG. About human tumor antigens to be used in immunotherapy. Semin Immunol. 2008; 20: 301-307
21. Coulie PG, Van den Eynde BJ, van der Bruggen P, et al. Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nat Rev Cancer. 2014; 14: 135-146
22. Gao J, Bernatchez C, Sharma P, et al. Advances in the development of cancer immunotherapies. Trends Immunol. 2013; 34: 90-98
23. Bazhin AV, Shevchenko I, Umansky V, et al. Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. Cancer Immunol Immunother. 2014; 63: 59-65
24. Niccolai E, Taddei A, Ricci F, et al. Intra-Tumoral IFNgamma-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. Clin Sci (Lond). 2016; 130: 247-258
25. Fukunaga A, Miyamoto M, Cho Y, et al. Cd8+ tumorinfiltrating lymphocytes together with CD4+ tumorinfiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004; 28: e26-e31
26. De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-Associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011; 208: 469-478
27. Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012; 12: 298-306
28. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10: 942-949
29. Amedei A, Niccolai E, Benagiano M, et al. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that enospecific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol Immunother. 2013; 62: 1249-1260
30. Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of Foxp3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006; 12: 5423-5434
31. He S, Fei M, Wu Y, et al. Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci. 2011; 12: 7424-7437
32. Vizio B, Novarino A, Giacobino A, et al. Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. Exp Ther Med. 2012; 4: 70-78
33. Yamamoto T, Yanagimoto H, Satoi S, et al. Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection. J Surg Res. 2012; 173: 299-308
34. Yang M, Ma C, Liu S, et al. HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. Immunol Cell Biol. 2010; 88: 165-171
35. Kunk PR, Bauer TW, Slingluff CL, et al. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer. 2016; 4: 14
36. Davis M, Conlon K, Bohac GC, et al. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J Immunother. 2012; 35: 629-640
37. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010; 59: 1593-1600
38. Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloidderived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011; 60: 1419-1430
39. Van Overmeire E, Laoui D, Keirsse J, et al. Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments ANC parallelisms with other tissues. Front Immunol. 2014; 5: 1-16
40. Kurahara H, Shinchi H, Mataki Y, et al. Significance of M2-polarized tumor-Associated macrophage in pancreatic cancer. J Surg Res. 2011; 167: e211-e219
41. Monjazeb AM, Hsiao HH, Sckisel GD, et al. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. J Immunotoxicol. 2012; 9: 248-258
42. Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 2015; 106: 945-950
43. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy-revisited. Nat Rev Drug Discov. 2011; 10: 591-600
44. Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta. 2007; 1776: 108-123
45. Gregoire M. What's the place of immunotherapy in malignant mesothelioma treatments?. Cell Adh Migr. 2010; 4: 153-161
46. Maus MV, Fraietta JA, Levine BL, et al. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol. 2014; 32: 189-225
47. Baxter D. Active and passive immunization for cancer. Hum Vaccin Immunother. 2014; 10: 2123-2129
48. American Cancer Society. Cancer immunotherapy. 2015. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003013-pdf.pdf. Accessed February 20, 2016
49. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006; 6: 714-727
50. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012; 12: 278-287
51. Jhaveri DT, Zheng L, Jaffee EM. Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. Semin Oncol. 2014; 41: 559-575
52. McLaughlin P, White CA, Grillo-Lopez AJ, et al. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park). 1998; 12: 1763-1769. Discussion 1769-1770, 1775-1767
53. Grillo-Lopez AJ, Hedrick E, Rashford M, et al. Rituximab: ongoing and future clinical development. Semin Oncol. 2002; 29: 105-112
54. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27: 2091-2096
55. Goffin JR, Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin Ther. 2013; 35: 1282-1303
56. Vrbic S, Pejcic I, Filipovic S, et al. Current and future anti-Her2 therapy in breast cancer. J BUON. 2013; 18: 4-16
57. Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol. 2015; 21: 9297-9316
58. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol. 2004; 22: 2610-2616
59. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205. J Clin Oncol. 2010; 28: 3605-3610
60. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321: 1801-1806
61. Cinar P, Tempero M.A. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J. 2012; 18: 653-664
62. Strumberg D, Schultheis B, Scheulen ME, et al. Phase II study of nimotuzumab, a humanized monoclonal antiepidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs. 2012; 30: 1138-1143
63. Su D, Jiao SC, Wang LJ, et al. Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Tumour Biol. 2014; 35: 2313-2318
64. Lyseng-Williamson KA, Robinson DM. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs. 2006; 20: 193-195
65. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005; 23: 8033-8040
66. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group B (CALGB 80303). J Clin Oncol. 2010; 28: 3617-3622
67. Beltran PJ, Mitchell P, Chung YA, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther. 2009; 8: 1095-1105
68. Calzone FJ, Cajulis E, Chung YA, et al. Epitope-specific mechanisms of IGF1R inhibition by ganitumab. PLoS One. 2013; 8: e55135
69. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009; 27: 5800-5807
70. Kindler HL, Richards DA, Garbo LE, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012; 23: 2834-2842
71. Fuchs CS, Azevedo S, Okusaka T, et al. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the gamma trial. Ann Oncol. 2015; 26: 921-927
72. Erkan M, Hausmann S, Michalski CW, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012; 9: 454-467
73. Neesse A, Frese KK, Bapiro TE, et al. CTGF antagonism with Mab Fg-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A. 2013; 110: 12325-12330
74. Ito A, Kondo S, Tada K, et al. Clinical development of immune checkpoint inhibitors. Biomed Res Int. 2015; 2015: 605478
75. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998; 392: 245-252
76. Okudaira K, Hokari R, Tsuzuki Y, et al. Blockade of B7-H1 or B7-Dc induces an anti-Tumor effect in a mouse pancreatic cancer model. Int J Oncol. 2009; 35: 741-749
77. Acuto O, Michel F. Cd28-mediated co-stimulation: A quantitative support for TCR signalling. Nat Rev Immunol. 2003; 3: 939-951
78. Mocellin S, Nitti D. CTLA-4 blockade and the renaissance of cancer immunotherapy. Biochim Biophys Acta. 2013; 1836: 187-196
79. Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science. 2006; 313: 1972-1975
80. Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11: 3887-3895
81. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291: 319-322
82. Quezada SA, Peggs KS, Simpson TR, et al. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev. 2011; 241: 104-118
83. Collins AV, Brodie DW, Gilbert RJ, et al. The interaction properties of costimulatory molecules revisited. Immunity. 2002; 17: 201-210
84. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723
85. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010; 33: 828-833
86. Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013; 36: 382-389
87. Weber J. Review: Anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007; 12: 864-872
88. Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675, 206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res. 2010; 16: 1042-1048
89. Sun Y, Wang Y, Zhao J, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006; 53: 143-151
90. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005; 23: 515-548
91. Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996; 8: 765-772
92. Nishimura H, Honjo T. PD-1: An inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001; 22: 265-268
93. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26: 677-704
94. He J, Hu Y, Hu M, et al. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep. 2015; 5: 13110
95. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007; 13: 2151-2157
96. Geng L, Huang D, Liu J, et al. B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol. 2008; 134: 1021-1027
97. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366: 2455-2465
98. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369: 134-144
99. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26: 5233-5239
100. Harris TJ, Drake CG. Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer. 2013; 1: 12
101. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007; 117: 1466-1476
102. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298: 850-854
103. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011; 17: 4550-4557
104. Liao Y, Ou J, Deng J, et al. Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer. Med Oncol. 2013; 30: 727
105. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood). 2011; 236: 567-579
106. Kilic A, Landreneau RJ, Luketich JD, et al. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res. 2011; 167: 207-210
107. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumorinfiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994; 86: 1159-1166
108. Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003; 26: 332-342
109. Junker N, Andersen MH, Wenandy L, et al. Bimodal ex vivo expansion of t cells from patients with head and neck squamous cell carcinoma: A prerequisite for adoptive cell transfer. Cytotherapy. 2011; 13: 822-834
110. Turcotte S, Gros A, Hogan K, et al. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol. 2013; 191: 2217-2225
111. Kershaw MH, Westwood JA, Slaney CY, et al. Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunol. 2014; 3: e16
112. Schmidt-Wolf IG, Finke S, Trojaneck B, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer. 1999; 81: 1009-1016
113. Wu C, Jiang J, Shi L, et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res. 2008; 28: 3997-4002
114. Jiang JT, Shen YP, Wu CP, et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol. 2010; 16: 6155-6162
115. Li W, Xu LP, DIZ L, et al. Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature. Oncol Lett. 2013; 5: 1427-1429
116. Chung MJ, Park JY, Bang S, et al. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunol Immunother. 2014; 63: 939-946
117. Shi S, Wang R, Chen Y, et al. Combining antiangiogenic therapy with adoptive cell immunetherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS One. 2013; 8: e65757
118. Wang M, Yin B, Wang HY, et al. Current advances in T-cell-based cancer immunotherapy. Immunotherapy. 2014; 6: 1265-1278
119. Kawaoka T, Oka M, Takashima M, et al. Adoptive immunotherapy for pancreatic cancer: cytotoxic t lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Oncol Rep. 2008; 20: 155-163
120. Jonckheere N, Van Seuningen I. The membrane-bound mucins: from cell signalling to transcriptional regulation and expression in epithelial cancers. Biochimie. 2010; 92: 1-11
121. Kondo H, Hazama S, Kawaoka T, et al. Adoptive immunotherapy for pancreatic cancer using muc1 peptidepulsed dendritic cells and activated T lymphocytes. Anticancer Res. 2008; 28: 379-387
122. Johnson LA, Heemskerk B, Powell DJ Jr, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol. 2006; 177: 6548-6559
123. Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-Term follow-up and correlates with response. Clin Cancer Res. 2015; 21: 1019-1027
124. Dodson LF, Hawkins WG, Goedegebuure P. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy. 2011; 3: 517-537
125. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009; 106: 3360-3365
126. Shirasu N, Shibaguci H, Kuroki M, et al. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen. Anticancer Res. 2010; 30: 2731-2738
127. Wilkie S, Burbridge SE, Chiapero-Stanke L, et al. Selective expansion of chimeric antigen receptor-Targeted T-cells with potent effector function using interleukin-4. J Biol Chem. 2010; 285: 25538-25544
128. Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor MRNA-engineered T cells induce anti-Tumor activity in solid malignancies. Cancer Immunol Res. 2014; 2: 112-120
129. Kleponis J, Skelton R, Zheng L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med. 2015; 12: 201-208
130. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003; 3: 630-641
131. Klebanoff CA, Acquavella N, Yu Z, et al. Therapeutic cancer vaccines: Are we there yet?. Immunol Rev. 2011; 239: 27-44
132. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst. 2012; 104: 599-613
133. Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J. 2013; 10: 239
134. Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs. 2010; 70: 1079-1098
135. Guo C, Manjili MH, Subjeck JR, et al. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013; 119: 421-475
136. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-422
137. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase ii randomized controlled trial of a poxviralbased PSA-Targeted immunotherapy in metastatic castrationresistant prostate cancer. J Clin Oncol. 2010; 28: 1099-1105
138. Disis ML. Mechanism of action of immunotherapy. Semin Oncol. 2014; 41(suppl 5): S3-S13
139. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480: 480-489
140. Oyasiji T, Ma WW. Novel adjuvant therapies for pancreatic adenocarcinoma. J Gastrointest Oncol. 2015; 6: 430-435
141. Galili U, Clark MR, Shohet SB, et al. Evolutionary relationship between the natural anti-GAL antibody and the GAL alpha 1-3GAL epitope in primates. Proc Natl Acad Sci U S A. 1987; 84: 1369-1373
142. Galili U. The alpha-GAL epitope and the anti-GAL antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol. 2005; 83: 674-686
143. Hardacre JM, Mulcahy M, Small W, et al. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: A phase 2 study. J Gastrointest Surg. 2013; 17: 94-100. Discussion p 100-101
144. Eager R, Nemunaitis J. GM-CSF gene-Transduced tumor vaccines. Mol Ther. 2005; 12: 18-27
145. Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factorsecreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011; 253: 328-335
146. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity. 2010; 33: 464-478
147. Schuler G. Dendritic cells in cancer immunotherapy. Eur J Immunol. 2010; 40: 2123-2130
148. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-Associated antigen peptides and clinical activity by vaccinations with {alpha}-Type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011; 29: 330-336
149. Wheeler CJ, Black KL. Vaccines for glioblastoma and highgrade glioma. Expert Rev Vaccines. 2011; 10: 875-886
150. Cheever MA, Higano CS. Provenge (Sipuleucel-T) in prostate cancer: the first FDA-Approved therapeutic cancer vaccine. Clin Cancer Res. 2011; 17: 3520-3526
151. Mayanagi S, Kitago M, Sakurai T, et al. Phase I pilot study of wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Sci. 2015; 106: 397-406
152. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms? tumor locus. Cell. 1990; 60: 509-520
153. Oji Y, Nakamori S, Fujikawa M, et al. Overexpression of the Wilms? Tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci. 2004; 95: 583-587
154. Rong Y, Qin X, Jin D, et al. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin Exp Med. 2012; 12: 173-180
155. Lin M, Yuan YY, Liu SP, et al. Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine. J Cancer Res Clin Oncol. 2015; 141: 1827-1833
156. Kubuschok B, Pfreundschuh M, Breit R, et al. Mutated Rastransfected, Ebv-Transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: A pilot trial. Hum Gene Ther. 2012; 23: 1224-1236
157. Abou-Alfa GK, Chapman PB, Feilchenfeldt J, et al. Targeting mutated K-Ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol. 2011; 34: 321-325
158. Yutani S, Komatsu N, Yoshitomi M, et al. A phase II study of a personalized peptide vaccination for chemotherapyresistant advanced pancreatic cancer patients. Oncol Rep. 2013; 30: 1094-1100
159. Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer. 2006; 95: 1474-1482
160. Middleton G, Silcocks P, Cox T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine Gv1001 in patients with locally advanced or metastatic pancreatic cancer (Telovac): An open-label, randomised, phase 3 trial. Lancet Oncol. 2014; 15: 829-840
161. Nishida S, Koido S, Takeda Y, et al. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother. 2014; 37: 105-114
162. Taniuchi K, Nakagawa H, Nakamura T, et al. Down-regulation of Rab6kifl/Kif20a, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res. 2005; 65: 105-112
163. Suzuki N, Hazama S, Ueno T, et al. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. J Immunother. 2014; 37: 36-42
164. Asahara S, Takeda K, Yamao K, et al. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med. 2013; 11: 291
165. Aurisicchio L, Ciliberto G. Genetic cancer vaccines: current status and perspectives. Expert Opin Biol Ther. 2012; 12: 1043-1058
166. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv Genet. 2005; 55: 25-40
167. Kaplan CD, Kruger JA, Zhou H, et al. A novel DNA vaccine encoding pdgfrbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. Vaccine. 2006; 24: 6994-7002
168. Xiang R, Luo Y, Niethammer AG, et al. Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol Rev. 2008; 222: 117-128
169. Chung VM, Hardwick N, Ellenhorn JDI, et al. A phase I study of an MVA vaccine targeting P53 in cancer. J Clin Oncol. 2013; 31: 3089
170. Drake CG. Combination immunotherapy approaches. Ann Oncol. 2012; 23(Suppl 8): viii41-viii46